ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Docetaxel: Drug information

Docetaxel: Drug information
(For additional information see "Docetaxel: Patient drug information" and see "Docetaxel: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Increased mortality:

Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, patients receiving higher doses, and patients with non-small cell lung cancer and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m2.

Hepatic function impairment:

Avoid the use of docetaxel in patients with bilirubin > ULN, or in patients with AST and/or ALT >1.5 times the ULN concomitant with alkaline phosphatase >2.5 times the ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 times the ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of docetaxel therapy.

Neutropenia:

Do not administer docetaxel to patients with neutrophil counts <1,500 cells/mm3. Monitor blood counts frequently as neutropenia may be severe and result in infection.

Hypersensitivity:

Do not administer docetaxel to patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80. Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the docetaxel infusion and administration of appropriate therapy.

Fluid retention:

Severe fluid retention occurred in 6.5% (6/92) of patients despite the use of dexamethasone premedication. It was characterized by 1 or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).

Brand Names: US
  • Taxotere [DSC]
Brand Names: Canada
  • Taxotere [DSC]
Pharmacologic Category
  • Antineoplastic Agent, Antimicrotubular;
  • Antineoplastic Agent, Taxane Derivative
Dosing: Adult

Note: Neutrophils should recover to >1,500/mm3 and platelets should recover to >100,000/mm3 prior to treatment with subsequent cycles. To reduce the potential risk and severity of tumor lysis syndrome, correct high uric acid serum levels and dehydration prior to docetaxel initiation.

Premedication: To reduce the incidence and severity of fluid retention and hypersensitivity reactions, the manufacturer recommends premedication for 3 days beginning 1 day prior to docetaxel administration with oral corticosteroids (eg, dexamethasone 8 mg orally twice daily for 3 days beginning 1 day prior to docetaxel). When prednisone is a backbone component of the antineoplastic regimen in the treatment of prostate cancer, administer dexamethasone 8 mg orally at 12 hours, 3 hours, and 1 hour prior to docetaxel. Data from 2 retrospective reviews describe the use a single dose of dexamethasone 10 or 20 mg IV prior to docetaxel (on the day of docetaxel infusion) to prevent hypersensitivity reactions (Lansinger 2021; Masood 2022).

Anal carcinoma, squamous cell, advanced

Anal carcinoma, squamous cell, advanced (off-label use): Modified DCF regimen: IV: 40 mg/m2 every 2 weeks (in combination with cisplatin, fluorouracil, and filgrastim) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Kim 2018).

Bladder cancer, advanced or metastatic

Bladder cancer, advanced or metastatic (off-label use): IV: 100 mg/m2 every 3 weeks (as a single agent) until disease progression or unacceptable toxicity (McCaffrey 1997) or 35 mg/m2 on days 1 and 8 of a 21-day cycle (in combination with gemcitabine and cisplatin) for at least 6 cycles or until disease progression or unacceptable toxicity (Pectasides 2002).

Bladder cancer, non–muscle invasive, refractory

Bladder cancer , non–m uscle invasive, refractory (off-label use):

Single-agent docetaxel: Intravesicular instillation: 75 mg per 100 mL NS; retain for 2 hours once weekly for 6 weeks during induction, followed 3 months later by (if complete response to induction) 75 mg per 100 mL NS once a month for up to 9 maintenance treatments (Barlow 2009; Barlow 2013; McKiernan 2006).

Docetaxel/gemcitabine: Intravesicular instillation: 37.5 mg per 50 mL NS; retain for 1 to 2 hours once weekly (gemcitabine is administered and dwelled for 1 to 1.5 hours, followed by docetaxel) for 6 weeks during induction, followed by (if recurrence free) once-monthly maintenance treatments for up to 24 months (Milbar 2017; Steinberg 2015; Steinberg 2020).

Breast cancer

Breast cancer:

Locally advanced or metastatic: IV: 60 to 100 mg/m2 every 3 weeks (as a single agent).

Operable, node-positive (adjuvant treatment): IV: TAC regimen: 75 mg/m2 every 3 weeks for 6 courses (in combination with doxorubicin and cyclophosphamide) (Mackey 2013; Martin 2005).

Adjuvant treatment (off-label dosing): IV: 75 mg/m2 every 21 days (in combination with cyclophosphamide) for 4 cycles (Jones 2006; Jones 2009) or 75 mg/m2 every 21 days (in combination with carboplatin and trastuzumab) for 6 cycles (Slamon 2011) or 75 mg/m2 every 21 days (in combination with cyclophosphamide and trastuzumab) for 4 cycles (Jones 2013).

Neoadjuvant treatment (off-label dosing): IV: 75 mg/m2 (cycle 1; if tolerated, may increase to 100 mg/m2 in subsequent cycles) every 21 days for a total of 4 cycles (in combination with trastuzumab and pertuzumab) (Gianni 2012) or 75 mg/m2 every 21 days for 6 cycles (in combination with carboplatin and WBC growth factor support) (Sharma 2017; Sharma 2018) or 75 mg/m2 every 21 days for 6 cycles (in combination with carboplatin, trastuzumab, and pertuzumab) (Schneeweiss 2013) or 75 mg/m2 initially (if tolerated, may increase to 100 mg/m2 in subsequent cycles) every 21 days for 3 cycles (following 3 cycles of fluorouracil, epirubicin, and cyclophosphamide and in combination with trastuzumab and pertuzumab) (Schneeweiss 2013).

Metastatic treatment (off-label dosing):

Every-3-week administration: IV: 75 mg/m2 (cycle 1; may increase to 100 mg/m2 in subsequent cycles) every 21 days for at least 6 cycles (in combination with trastuzumab and pertuzumab) (Baselga 2012; Swain 2013) or 100 mg/m2 every 21 days (in combination with trastuzumab) for at least 6 cycles (Marty 2005) or 75 mg/m2 every 21 days (in combination with capecitabine) until disease progression or unacceptable toxicity (O’Shaughnessy 2002) or 60 mg/m2, 75 mg/m2, or 100 mg/m2 every 21 days for at least 6 cycles until disease progression, unacceptable toxicity, or discontinuation (Harvey 2006).

Weekly administration: IV: 40 mg/m2 once a week (as a single agent) for 6 weeks followed by a 2-week rest, repeat until disease progression or unacceptable toxicity (Burstein 2000) or 35 mg/m2 once weekly for 3 weeks, followed by a 1-week rest, may increase to 40 mg/m2 once weekly for 3 weeks followed by a 1-week rest with cycle 2 (Rivera 2008) or 35 mg/m2 once weekly (in combination with trastuzumab) for 3 weeks followed by a 1-week rest; repeat until disease progression or unacceptable toxicity (Esteva 2002).

Esophageal cancer

Esophageal cancer (off-label use):

Sequential chemotherapy and chemoradiation: IV: Induction: 75 mg/m2 on days 1 and 22 (in combination with cisplatin) for 2 cycles, followed by chemoradiation: 20 mg/m2 weekly for 5 weeks (in combination with cisplatin and radiation) (Ruhstaller 2009).

Definitive chemoradiation: IV: 60 mg/m2 on days 1 and 22 (in combination with cisplatin and radiation) for 1 cycle (Li 2010).

Locally advanced, resectable gastroesophageal junction adenocarcinoma: IV: 50 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin; FLOT regimen) for 4 preoperative and 4 postoperative cycles (Al-Batran 2019).

Locally advanced or metastatic disease: IV: 75 mg/m2 on day 1 every 3 weeks (in combination with cisplatin and fluorouracil) (Ajani 2007; Van Cutsem 2006) or 40 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and cisplatin) until disease progression or unacceptable toxicity (Shah 2015) or 50 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Al-Batran 2008) or 35 mg/m2 on days 1, 8, 15, 29, 36, 43, 50, and 57 (in combination with cisplatin, fluorouracil, and radiotherapy; neoadjuvant setting) (Pasini 2013).

Ewing sarcoma, recurrent or refractory

Ewing sarcoma, recurrent or refractory (off-label use; based on limited data): IV: 75 to 100 mg/m2 on day 8 of a 21-day cycle (in combination with gemcitabine) (Fox 2012; Navid 2008).

Gastric adenocarcinoma

Gastric adenocarcinoma : IV: 75 mg/m2 every 3 weeks (in combination with cisplatin and fluorouracil).

Sequential chemotherapy and chemoradiation (off-label dosing): Induction: IV: 75 mg/m2 on days 1 and 22 (in combination with cisplatin) for 2 cycles, followed by chemoradiation: 20 mg/m2 weekly for 5 weeks (in combination with cisplatin and radiation) (Ruhstaller 2009).

Locally advanced resectable disease (off-label dosing): IV: 50 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin; FLOT regimen) for 4 preoperative and 4 postoperative cycles (Al-Batran 2019).

Locally advanced or metastatic disease (off-label dosing): IV: 40 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and cisplatin) until disease progression or unacceptable toxicity (Shah 2015) or 50 mg/m2 on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Al-Batran 2008).

Head and neck cancer

Head and neck cancer: IV: 75 mg/m2 every 3 weeks (in combination with cisplatin and fluorouracil) for 3 or 4 cycles, followed by radiation therapy (Posner 2007; Vermorken 2007).

Nasopharyngeal carcinoma, locally advanced: IV: 60 mg/m2 every 3 weeks (in combination with cisplatin and fluorouracil) for 3 induction cycles, followed by concurrent chemoradiotherapy (Sun 2016) or 75 mg/m2 every 3 weeks (in combination with cisplatin) for 2 cycles, followed by chemoradiotherapy (Hui 2009).

Non-small cell lung cancer

Non-small cell lung cancer: IV: 75 mg/m2 every 3 weeks (as a single agent or in combination with cisplatin).

Off-label combinations: IV: 75 mg/m2 every 3 weeks (in combination with carboplatin) for at least 6 cycles or until disease progression or unacceptable toxicity (Fossella 2003) or 85 mg/m2 on day 8 of a 3-week treatment cycle (in combination with gemcitabine) for 8 cycles or until disease progression or unacceptable toxicity (Pujol 2005) or 75 mg/m2 every 3 weeks (in combination with ramucirumab) until disease progression or unacceptable toxicity (Garon 2014).

Osteosarcoma, recurrent or refractory

Osteosarcoma, recurrent or refractory (off-label use): IV: 75 to 100 mg/m2 on day 8 of a 21-day cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (Fox 2012; Navid 2008; Palmerini 2016).

Ovarian cancer

Ovarian cancer (off-label use): IV: 60 mg/m2 every 3 weeks (in combination with carboplatin) for up to 6 cycles (Markman 2001) or 75 mg/m2 every 3 weeks (in combination with carboplatin) for 6 cycles (Vasey 2004) or 35 mg/m2 (maximum dose: 70 mg) weekly for 3 weeks followed by a 1-week rest (in combination with carboplatin) (Kushner 2007).

Prostate cancer, castration-resistant, metastatic

Prostate cancer, castration-resistant, metastatic: IV: 75 mg/m2 every 3 weeks (in combination with prednisone) (Tannock 2004).

Docetaxel/carboplatin (off-label combination): IV: 75 mg/m2 every 3 weeks (in combination with carboplatin) for at least 4 cycles or until disease progression or unacceptable toxicity (Aparicio 2013).

Prostate cancer, hormone-sensitive, metastatic

Prostate cancer, hormone-sensitive, metastatic (off-label use): IV: 75 mg/m2 on day 1 every 3 weeks (in combination with androgen-deprivation therapy and prednisolone) for 6 cycles (James 2016) or 75 mg/m2 on day 1 every 3 weeks (in combination with androgen-deprivation therapy; daily prednisone not required) for 6 cycles (Sweeney 2015) or 75 mg/m2 on day 1 every 3 weeks (in combination with darolutamide and androgen-deprivation therapy) for 6 cycles; darolutamide was continued after the 6 docetaxel cycles (Smith 2022) or 75 mg/m2 (maximum dose: 150 mg) on day 1 every 3 weeks (in combination with abiraterone, prednisone, and androgen-deprivation therapy) for 6 cycles; abiraterone and prednisone were continued after the 6 docetaxel cycles (Fizazi 2022).

Small cell lung cancer, relapsed

Small cell lung cancer, relapsed (off-label use): IV: 100 mg/m2 every 3 weeks (Smyth 1994).

Soft tissue sarcoma, recurrent or progressive

Soft tissue sarcoma, recurrent or progressive (off-label use): IV: 100 mg/m2 on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) (Leu 2004; Maki 2007).

Thyroid carcinoma, anaplastic

Thyroid carcinoma, anaplastic (off-label use):

Adjuvant or radiosensitizing therapy: IV: 60 mg/m2 on day 1 every 3 to 4 weeks (in combination with doxorubicin and pegfilgrastim) for ~4 cycles (ATA [Smallridge 2012]; Foote 2011) or 20 mg/m2 once weekly (in combination with doxorubicin) (ATA [Smallridge 2012]).

Advanced or metastatic disease: IV: 60 mg/m2 on day 1 every 3 to 4 weeks (in combination with doxorubicin and pegfilgrastim) or 20 mg/m2 once weekly (in combination with doxorubicin) (ATA [Smallridge 2012]).

Unknown primary, adenocarcinoma

Unknown primary, adenocarcinoma (off-label use): IV: 65 mg/m2 every 3 weeks (in combination with carboplatin) (Greco 2000) or 75 mg/m2 on day 8 of a 3-week treatment cycle (in combination with gemcitabine) for up to 6 cycles (Pouessel 2004) or 60 mg/m2 on day 1 of a 3-week treatment cycle (in combination with cisplatin) (Mukai 2010).

Uterine leiomyosarcoma, advanced or high-grade

Uterine leiomyosarcoma, advanced or high-grade (off-label use):

Unresectable leiomyosarcoma: IV: 100 mg/m2 (75 mg/m2 if received prior radiation therapy) on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim) for 6 cycles (Hensley 2002).

High-grade leiomyosarcoma, previously untreated: IV: 75 mg/m2 on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) for 4 cycles (Hensley 2009) or 75 mg/m2 on day 8 of a 3-week treatment cycle (in combination with gemcitabine) for up to 6 cycles in the absence of disease progression or unacceptable toxicity (Seddon 2017).

Metastatic leiomyosarcoma: IV: 75 mg/m2 (60 mg/m2 if received prior radiation therapy) on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) until disease progression or unacceptable toxicity (Hensley 2015).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Renal excretion is minimal (~6%), therefore, the need for dosage adjustments for renal dysfunction is unlikely (Janus 2010; Li 2007). Not removed by hemodialysis, may be administered before or after hemodialysis (Janus 2010).

Dosing: Hepatic Impairment: Adult

Note: The alcohol content of the docetaxel formulation should be taken into account when administering to patients with hepatic impairment.

Total bilirubin > ULN or AST and/or ALT >1.5 times ULN concomitant with alkaline phosphatase >2.5 times ULN: Avoid docetaxel use.

Isolated transaminase elevations >1.5 times ULN: Consider docetaxel dose modification.

Hepatic impairment dosing adjustment specific for gastric or head and neck cancer:

AST/ALT >2.5 to ≤5 times ULN and alkaline phosphatase ≤2.5 times ULN: Administer 80% of dose.

AST/ALT >1.5 to ≤5 times ULN and alkaline phosphatase >2.5 to ≤5 times ULN: Administer 80% of dose.

AST/ALT >5 times ULN and /or alkaline phosphatase >5 times ULN: Discontinue docetaxel.

The following adjustments have also been used (Floyd 2006):

Transaminases 1.6 to 6 times ULN: Administer 75% of dose.

Transaminases >6 times ULN: Use clinical judgment.

Dosing: Pediatric

(For additional information see "Docetaxel: Pediatric drug information")

Note: Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols: Premedicate with corticosteroids, beginning the day before docetaxel administration (administer corticosteroids for 1 to 3 days), to reduce the severity of hypersensitivity reactions and pulmonary/peripheral edema. For adults, the manufacturer recommends dexamethasone 16 mg (8 mg twice daily) orally for 3 days. In one pediatric clinical trial, dexamethasone 3 mg/m2 orally or IV every 6 hours for 2 doses, starting 12 hours before docetaxel administration has been described (Zwerdling 2006). Docetaxel is associated with a low emetic potential (POGO [Dupuis 2011]); an antiemetic may be recommended to prevent nausea and vomiting (POGO [Dupuis 2013]).

Sarcomas, Ewing Sarcoma; osteosarcoma

Sarcomas, Ewing Sarcoma; osteosarcoma (recurrent or progressive): Limited data available:

Mora 2009: G + D regimen: Children and Adolescents: IV: 100 mg/m2 over 2 to 4 hours on Day 8 of a 21-day cycle in combination with gemcitabine.

Rapkin 2012: GEMDOX regimen:

Infants: IV: 2.5 mg/kg over 1 hour on Day 8 of a 21-day cycle in combination with gemcitabine.

Children and Adolescents: IV: 75 mg/m2 over 1 hour on Day 8 of a 21-day cycle in combination with gemcitabine.

Hepatoblastoma

Hepatoblastoma (refractory or relapsed): Limited data available, case-series reports (George 2012): Infants and Children:

Patient weight <10 kg: IV: 3.3 mg/kg as a 1-hour infusion every 21 days.

Patient weight >10 kg: IV: 100 mg/m2 given as a 1-hour infusion every 21 days.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing adjustment for toxicity: The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.

Adult: Note: Toxicity includes febrile neutropenia, neutrophils <500/mm3 for >1 week, severe or cumulative cutaneous reactions; in non-small cell lung cancer, this may also include platelets <25,000/mm3 and other grade 3/4 nonhematologic toxicities.

Breast cancer (single agent): Patients dosed initially at 100 mg/m2 (adult); reduce dose to 75 mg/m2 (adult); Note: If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m2 (adult) or therapy should be discontinued; discontinue for peripheral neuropathy ≥ grade 3. Patients initiated at 60 mg/m2 (adult) who do not develop toxicity may tolerate higher doses.

Breast cancer, adjuvant treatment (combination chemotherapy): TAC regimen should be administered when neutrophils are ≥1,500/mm3. Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, moderate neurosensory effects (signs/symptoms) or grade 3 or 4 stomatitis should receive a reduced dose (60 mg/m2 in adults) of docetaxel. Discontinue therapy with persistent toxicities after dosage reduction.

Non-small cell lung cancer:

Monotherapy: Patients dosed initially at 75 mg/m2 (adult) should have dose held until toxicity is resolved, then resume at 55 mg/m2 (adult); discontinue for peripheral neuropathy ≥ grade 3.

Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m2 (adult) should have the docetaxel dosage reduced to 65 mg/m2 (adult) in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m2 (adult).

Prostate cancer: Reduce dose to 60 mg/m2 (adult); discontinue therapy if toxicities persist at lower dose.

Gastric cancer, head and neck cancer: Note: Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia >7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, further reduce dose to 60 mg/m2 (adult). Dosing with neutropenic complications in subsequent cycles should be further reduced to 45 mg/m2 (adult). Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m2 to 60 mg/m2 (adult dosing). Discontinue therapy for persistent toxicities.

Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:

Diarrhea, grade 3:

First episode: Reduce fluorouracil dose by 20%.

Second episode: Reduce docetaxel dose by 20%.

Diarrhea, grade 4:

First episode: Reduce fluorouracil and docetaxel doses by 20%.

Second episode: Discontinue treatment.

Stomatitis, grade 3:

First episode: Reduce fluorouracil dose by 20%.

Second episode: Discontinue fluorouracil for all subsequent cycles.

Third episode: Reduce docetaxel dose by 20%.

Stomatitis, grade 4:

First episode: Discontinue fluorouracil for all subsequent cycles.

Second episode: Reduce docetaxel dose by 20%.

Dosing: Kidney Impairment: Pediatric

There are no pediatric specific recommendations available; refer to protocols; based on experience in adult patients, renal excretion is minimal; therefore, the need for dosage adjustments for renal dysfunction is unlikely (Janus 2010; Li 2007). Not removed by hemodialysis; may be administered before or after hemodialysis (Janus 2010).

Dosing: Hepatic Impairment: Pediatric

There are no pediatric specific recommendations available; refer to protocols; based on experience in adult patients, dosage adjustment suggested based on elevations of liver enzymes and/or total bilirubin levels.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Obesity: Adult

American Society of Clinical Oncology guidelines for appropriate chemotherapy dosing in adults with cancer with a BMI ≥30 kg/m2: Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for patients with a BMI <30 kg/m2; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing with subsequent cycles, if cause of toxicity (eg, hepatic or renal impairment) is clearly established and fully resolved (ASCO [Griggs 2021]).

Dosing: Adjustment for Toxicity: Adult

Note: Neutrophils should recover to >1,500/mm3 and platelets should recover to >100,000/mm3 prior to treatment with subsequent cycles. Hematologic toxicity includes febrile neutropenia, neutrophils <500/mm3 for >1 week, severe or cumulative cutaneous reactions; in non-small cell lung cancer, this may also include platelet nadir <25,000/mm3 and other grade 3/4 nonhematologic toxicities.

Dermatologic toxicity: Consider permanent docetaxel discontinuation in patients who develop severe cutaneous adverse reactions.

Hypersensitivity: Immediately discontinue docetaxel for severe hypersensitivity reaction (and administer appropriate medical management). Do not rechallenge if severe hypersensitivity occurred.

Neurosensory symptoms (eg, paresthesia, dysesthesia, pain): Adjust docetaxel dose for severe neurosensory symptoms; discontinue docetaxel for persistent symptoms.

Ocular disorders: Discontinue docetaxel if cystoid macular edema is diagnosed (consider alternate non-taxane therapies). A prompt comprehensive ophthalmic exam is recommended if vision impairment occurs.

Also refer to specific reference/protocol for dosage adjustments for off-label uses, doses, or combinations.

Breast cancer (single agent): Patients dosed initially at 100 mg/m2; reduce dose to 75 mg/m2; Note: If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m2 or therapy should be discontinued; discontinue for peripheral neuropathy ≥ grade 3. Patients initiated at 60 mg/m2 who do not develop toxicity may tolerate higher doses.

Breast cancer, adjuvant treatment (combination chemotherapy): TAC regimen should be administered when neutrophils are ≥1,500/mm3. Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, moderate neurosensory effects (signs/symptoms) or grade 3 or 4 stomatitis should receive a reduced dose (60 mg/m2) of docetaxel. Discontinue therapy with persistent toxicities after dosage reduction.

Non-small cell lung cancer:

Monotherapy: Patients dosed initially at 75 mg/m2 should have dose held until toxicity is resolved, then resume at 55 mg/m2; discontinue for peripheral neuropathy ≥ grade 3.

Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m2 should have the docetaxel dosage reduced to 65 mg/m2 in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m2.

Prostate cancer: Reduce dose to 60 mg/m2; discontinue therapy if toxicities persist at lower dose.

Gastric cancer, head and neck cancer: Note: Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia >7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, reduce dose to 60 mg/m2. Dosing with neutropenic complications in subsequent cycles should be further reduced (following neutrophil recovery to ≥1,500/mm3) to 45 mg/m2. Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m2 to 60 mg/m2 (following platelet recovery to >100,000/mm3). Discontinue therapy for persistent toxicities.

Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:

Diarrhea, grade 3:

First episode: Reduce fluorouracil dose by 20%.

Second episode: Reduce docetaxel dose by 20%.

Diarrhea, grade 4:

First episode: Reduce fluorouracil and docetaxel doses by 20%.

Second episode: Discontinue treatment.

Stomatitis, grade 3:

First episode: Reduce fluorouracil dose by 20%.

Second episode: Discontinue fluorouracil for all subsequent cycles.

Third episode: Reduce docetaxel dose by 20%.

Stomatitis, grade 4:

First episode: Discontinue fluorouracil for all subsequent cycles.

Second episode: Reduce docetaxel dose by 20%.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Concentrate, Intravenous:

Taxotere: 20 mg/mL (1 mL [DSC]); 80 mg/4 mL (4 mL [DSC]) [contains alcohol, usp, polysorbate 80]

Generic: 20 mg/mL (1 mL); 80 mg/4 mL (4 mL); 160 mg/8 mL (8 mL); 200 mg/10 mL (10 mL [DSC])

Concentrate, Intravenous [preservative free]:

Generic: 20 mg/mL (1 mL); 160 mg/8 mL (8 mL [DSC])

Solution, Intravenous:

Generic: 20 mg/2 mL (2 mL); 80 mg/8 mL (8 mL); 160 mg/16 mL (16 mL); 20 mg/mL (1 mL [DSC]); 80 mg/4 mL (4 mL [DSC]); 160 mg/8 mL (8 mL [DSC])

Generic Equivalent Available: US

Yes

Dosage Forms Considerations

Non-alcohol formulation (Eagle/Teikuku pharmaceuticals): Solution, Intravenous [alcohol-free]: Generic: 20 mg/mL (1 mL; single-dose vial); 80 mg/4 mL (4 mL multi-dose vial); 160 mg/8 mL (8 mL; multi-dose vial)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Concentrate, Intravenous:

Taxotere: 80 mg/2 mL ([DSC]) [contains alcohol, usp, polysorbate 80]

Generic: 20 mg/mL (1 mL, 4 mL, 8 mL)

Solution, Intravenous:

Generic: 10 mg/mL (2 mL, 8 mL, 16 mL)

Administration: Adult

IV: Infuse over 1 hour through nonsorbing polyethylene lined (non-DEHP) tubing. Note: Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to reduce the incidence and severity of hypersensitivity reactions and fluid retention (see "Dosing: Adult" for premedication information). Monitor for hypersensitivity reactions, especially during the first and second infusion. Some docetaxel formulations contain alcohol (content varies by formulation); use with caution in patients for whom alcohol intake should be avoided or minimized (a non-alcohol generic formulation [20 mg/mL] is also available).

The use of an in-line filter is not necessary during administration of the Taxotere brand; according to the manufacturer, studies have not been performed to determine the compatibility of IV filters for administration and filters are not recommended for use with docetaxel (data on file [Sanofi Aventis 2016]). The use of an inline filter is also not recommended for administration of the non-alcohol docetaxel formulation (data on file [Eagle Pharmaceuticals 2016]).

Irritant with vesicant-like properties; avoid extravasation. Assure proper needle or catheter position prior to administration.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding the use of warm or cold compresses (Perez Fidalgo 2012; Polovich 2009).

Intravesicular administration for non–muscle invasive bladder cancer (off-label use): Empty bladder prior to docetaxel instillation; instruct patient to retain for 1 to 2 hours (based on protocol) and then empty bladder (Barlow 2009; Barlow 2013; McKiernan 2006; Milbar 2017; Steinberg 2015; Steinberg 2020).

Administration: Pediatric

Administer as an IV infusion over 1 hour through nonsorbing polyethylene-lined (non-DEHP) tubing; in-line filter is not necessary (the use of a filter during administration is not recommended by the manufacturer). Infusion should be completed within 4 hours of preparation. Note: Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to prevent hypersensitivity reactions and pulmonary/peripheral edema. Some docetaxel formulations contain alcohol (content varies by formulation); use with caution in patients for whom alcohol intake should be avoided or minimized.

Irritant with vesicant-like properties; avoid extravasation. Assure proper needle or catheter position prior to administration. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding the use of warm or cold compresses (Pérez Fidalgo 2012; Polovich 2009).

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).

Use: Labeled Indications

Breast cancer: Treatment of breast cancer (locally advanced/metastatic) after prior chemotherapy failure; adjuvant treatment (in combination with doxorubicin and cyclophosphamide) of operable node-positive breast cancer.

Gastric adenocarcinoma: Treatment of advanced gastric adenocarcinoma, including gastroesophageal junction adenocarcinoma (in combination with cisplatin and fluorouracil) in patients who have not received prior chemotherapy for advanced disease.

Head and neck cancer: Treatment (induction) of locally advanced squamous cell head and neck cancer (in combination with cisplatin and fluorouracil).

Non-small cell lung cancer: Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy; treatment of previously untreated unresectable locally advanced or metastatic NSCLC (in combination with cisplatin).

Prostate cancer: Treatment of metastatic castration-resistant prostate cancer (in combination with prednisone).

Use: Off-Label: Adult

Anal carcinoma (squamous cell), advanced; Bladder cancer, advanced or metastatic; Bladder cancer, non–muscle invasive, refractory (intravesical); Esophageal cancer, chemoradiation; Esophageal cancer, locally advanced or metastatic disease; Ewing sarcoma (recurrent or refractory); Osteosarcoma (recurrent or refractory); Ovarian cancer; Prostate cancer, metastatic, hormone-sensitive; Small cell lung cancer, relapsed; Soft tissue sarcoma (recurrent or progressive); Thyroid carcinoma, anaplastic; Unknown primary, adenocarcinoma; Uterine leiomyosarcoma (advanced or high-grade)

Medication Safety Issues
Sound-alike/look-alike issues:

DOCEtaxel may be confused with cabazitaxel, PACLitaxel (conventional), PACLitaxel (protein bound).

Taxotere may be confused with Abraxane, Taxol.

High alert medication:

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.

Administration issues:

Multiple concentrations: Docetaxel is available as a one-vial formulation at concentrations of 10 mg/mL (generic formulation) and 20 mg/mL (concentrate/solution; Taxotere or non-alcohol generic formulation). Admixture errors have occurred due to the availability of various docetaxel concentrations.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported for docetaxel monotherapy; frequency may vary depending on diagnosis, dose, liver function, prior treatment, and premedication.

>10%:

Dermatologic: Alopecia (56% to 76%, can be permanent), dermatological reaction (20% to 48%; severe dermatological reaction: 5%), nail disease (11% to 41%)

Endocrine & metabolic: Fluid retention (26% to 60%)

Gastrointestinal: Diarrhea (23% to 43%; severe diarrhea: ≤6%), nausea (34% to 42%; severe nausea: ≤5%), stomatitis (19% to 53%; grades 3/4: 2%), vomiting (22% to 23%; severe vomiting: ≤5%)

Hematologic & oncologic: Anemia (65% to 97%; grades 3/4: 8% to 9%), febrile neutropenia (5% to 14%), leukopenia (84% to 99%; grades 3/4: 49%; grade 4: 32% to 44%), neutropenia (84% to 99%; grades 3/4: 65%; grade 4: 75% to 86%; nadir [median]: 7 days, duration [severe neutropenia]: 7 days), thrombocytopenia (7% to 14%; grades 3/4: 3%; grade 4: 1%)

Hepatic: Increased serum alanine aminotransferase (≤19%), increased aspartate aminotransferase (≤19%)

Hypersensitivity: Hypersensitivity reaction (6% to 21%, including back pain, chest tightness, chills, drug fever, dyspnea, flushing, skin rash; severe hypersensitivity reaction: 3% to 4%)

Infection: Infection (1% to 34%; severe infection: 2% to 6%)

Nervous system: Central nervous system toxicity (20% to 58%; including dysesthesia: ≤6%, paresthesia: ≤6%)

Neuromuscular & skeletal: Asthenia (53% to 66%; severe weakness: 13% to 18%), myalgia (3% to 23%; severe myalgia: 2%), neuromuscular reaction (16%)

Respiratory: Pulmonary disease (41%)

Miscellaneous: Fever (31% to 35%)

1% to 10%:

Cardiovascular: Hypotension (3%)

Gastrointestinal: Dysgeusia (6%)

Hepatic: Increased serum alkaline phosphatase (7%), increased serum bilirubin (9%)

Local: Infusion site reaction (4%; including erythema at injection site, exfoliation of skin, inflammation at injection site, injection site extravasation, local dryness of skin, skin discoloration at injection site, swelling at injection site [vein])

Nervous system: Peripheral motor neuropathy (4%; severe; mainly distal extremity weakness)

Neuromuscular and skeletal: Arthralgia (3% to 9%)

<1%: Dermatologic: Onycholysis

Frequency not defined:

Cardiovascular: Decreased left ventricular ejection fraction, localized phlebitis

Dermatologic: Localized erythema of the extremities, nail depigmentation, nail hyperpigmentation

Nervous system: Fatigue

Postmarketing:

Cardiovascular: Acute myocardial infarction, atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac failure, chest pain, deep vein thrombosis, ECG abnormality, hypertension, pulmonary embolism, sinus tachycardia, syncope, tachycardia, thrombophlebitis, unstable angina pectoris

Dermatologic: Acute generalized exanthematous pustulosis, cutaneous lupus erythematosus, dermatological reaction (injection site recall at previous site of extravasation), erythema multiforme, palmar-plantar erythrodysesthesia, skin changes (scleroderma-like), Stevens-Johnson syndrome, toxic epidermal necrolysis

Endocrine & metabolic: Electrolyte disorder, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia

Gastrointestinal: Abdominal pain, anorexia, colitis, constipation, duodenal ulcer, enterocolitis, esophagitis, gastrointestinal hemorrhage, gastrointestinal perforation, intestinal obstruction, ischemic colitis, neutropenic enterocolitis

Hematologic & oncologic: Acute myelocytic leukemia, bleeding tendency disorder, disseminated intravascular coagulation, lymphedema (peripheral), myelodysplastic syndrome, non-Hodgkin's lymphoma, tumor lysis syndrome

Hepatic: Acute hepatic failure (Morgan 2011), hepatitis

Hypersensitivity: Anaphylactic shock, anaphylaxis

Infection: Sepsis

Nervous system: Confusion, loss of consciousness (transient), pain, seizure

Neuromuscular & skeletal: Myositis

Ophthalmic: Conjunctivitis, cystoid macular edema, disease of the lacrimal apparatus (duct obstruction), epiphora (more common with weekly administration [Kintzel 2006]), lacrimation, visual disturbance (transient)

Otic: Auditory disturbance, hearing loss, ototoxicity

Renal: Renal failure syndrome, renal insufficiency, renal neoplasm

Respiratory: Acute respiratory distress, interstitial pulmonary disease, pneumonia (interstitial), pneumonitis, pulmonary edema, pulmonary fibrosis, respiratory failure

Miscellaneous: Multi-organ failure, radiation recall phenomenon

Contraindications

History of severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1,500/mm3.

Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding.

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Neutropenia may be severe and may result in infection; the dose-limiting toxicity is neutropenia. Patients with increased LFTs experienced more episodes of neutropenia with a greater number of severe infections.

• Cutaneous reactions: Cutaneous reactions, including erythema (with edema) and desquamation, have been reported. Severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis have been reported and may be associated with docetaxel.

• Extravasation: Docetaxel is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

• Fluid retention: Severe fluid retention, characterized by pleural effusion (requiring immediate drainage), ascites with pronounced abdominal distention, peripheral edema (poorly tolerated), dyspnea at rest, cardiac tamponade, and/or generalized edema, has been reported (despite the use of premedication with dexamethasone). Fluid retention may begin as lower extremity peripheral edema and become generalized with a median weight gain of 2 kg. In 92 patients with breast cancer who received corticosteroid premedication, moderate and severe fluid retention occurred in ~27% and ~7%, respectively; the median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m2; fluid retention resolves in a median of 16 weeks (range: up to 42 weeks) after discontinuation. Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to reduce the incidence and severity of fluid retention. Closely monitor patients with existing effusions.

• GI toxicity: Enterocolitis and neutropenic colitis (typhlitis) have occurred with docetaxel (either as a single agent or in combination with other chemotherapy) and despite administration of filgrastim; may occur at any time and could be fatal on the first day of symptom onset. Use with caution in patients with neutropenia, particularly those at increased risk for developing GI complications. Patients should report new-onset or worsening symptoms of GI toxicity.

• Hypersensitivity: Severe hypersensitivity reactions have been reported despite dexamethasone premedication. Severe hypersensitivity reactions have been characterized by generalized rash/erythema, hypotension, bronchospasm, and/or fatal anaphylaxis. Patients with a history of hypersensitivity reaction to paclitaxel may develop hypersensitivity to docetaxel; may be severe or fatal (including anaphylaxis); monitor patients with paclitaxel hypersensitivity closely during initiation of docetaxel therapy. Minor reactions including flushing or localized skin reactions may also occur.

• Neurosensory symptoms: Severe neurosensory symptoms (paresthesia, dysesthesia, pain) have been observed; reversal of symptoms may be delayed after discontinuation. Severe peripheral motor neuropathy manifesting as distal extremity weakness has been reported.

• Ocular adverse effects: Cystoid macular edema (CME) has been reported; if vision impairment occurs, a prompt comprehensive ophthalmic exam is recommended. In a study of patients receiving docetaxel for the adjuvant treatment of breast cancer, a majority of patients experienced tearing, which occurred in patients with and without lacrimal duct obstruction at baseline. Onset was generally after cycle 1, but subsided in most patients within 4 months after therapy completion (Chan 2013).

• Secondary malignancies: Second primary malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma, and renal cancer have occurred in patients several months or years after receiving docetaxel-containing regimens. Treatment-related AML or MDS has occurred in patients receiving docetaxel in combination with anthracyclines and/or cyclophosphamide (with or without fluorouracil), including patients who received docetaxel-containing regimens as adjuvant therapy.

• Treatment-related mortality: Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, those receiving higher doses, and patients with non-small cell lung cancer and a history of prior treatment with platinum derivatives who receive single-agent docetaxel at a dose of 100 mg/m2.

• Tumor lysis syndrome: Tumor lysis syndrome (TLS) has occurred; closely monitor patients at high risk of TLS (eg, renal impairment, hyperuricemia, bulky tumor) prior to therapy and periodically during therapy.

• Weakness: Fatigue and weakness (may be severe) have been reported; symptoms may last a few days up to several weeks. In patients with progressive disease, weakness may be associated with a decrease in performance status.

Disease-related concerns:

• Heart failure: In a scientific statement from the American Heart Association, docetaxel has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).

• Hepatic impairment: Patients with bilirubin elevations or abnormal transaminases (with concurrent abnormal alkaline phosphatase) are at increased risk for severe neutropenia, neutropenic fever, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated transaminase elevations >1.5 times ULN also had a higher rate of neutropenic fever.

Dosage form specific issues:

• Alcohol content: Some docetaxel formulations contain alcohol (content varies by formulation), which may affect the central nervous system and cause symptoms of alcohol intoxication. Consider alcohol content and use with caution in patients for whom alcohol intake should be avoided or minimized. Patients should avoid driving or operating machinery immediately after the infusion. An FDA-approved non-alcohol generic formulation (20 mg/mL) is available.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Metabolism/Transport Effects

Substrate of CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Anthracyclines: Taxane Derivatives may enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities. Risk D: Consider therapy modification

Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. Risk X: Avoid combination

BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. Risk X: Avoid combination

Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. Risk C: Monitor therapy

Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy

Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk X: Avoid combination

Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. Risk X: Avoid combination

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy

Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test. Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider therapy modification

COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector). Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters). Risk D: Consider therapy modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor therapy

COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider therapy modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). Risk C: Monitor therapy

COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of DOCEtaxel. Risk C: Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DOCEtaxel. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of DOCEtaxel. Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities. Risk D: Consider therapy modification

Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider therapy modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). Risk X: Avoid combination

Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider therapy modification

Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination

Dronedarone: May increase the serum concentration of DOCEtaxel. Management: Avoid this combination whenever possible. If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.). Risk D: Consider therapy modification

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. Risk X: Avoid combination

Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. Risk C: Monitor therapy

Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider therapy modification

Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy. Risk D: Consider therapy modification

Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider therapy modification

Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Risk D: Consider therapy modification

Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. Risk X: Avoid combination

Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. Risk C: Monitor therapy

Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. Risk C: Monitor therapy

Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. Risk C: Monitor therapy

Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Risk D: Consider therapy modification

Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. Management: Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane before platinum is likely warranted Risk D: Consider therapy modification

Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. Risk C: Monitor therapy

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Risk X: Avoid combination

Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification

Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider therapy modification

Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider therapy modification

Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rubella- or Varicella-Containing Live Vaccines. Risk X: Avoid combination

Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). Risk X: Avoid combination

Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

SORAfenib: May increase the serum concentration of DOCEtaxel. Risk C: Monitor therapy

Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk C: Monitor therapy

Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). Risk X: Avoid combination

Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid combination

Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. Risk X: Avoid combination

Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. Risk X: Avoid combination

Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. Risk X: Avoid combination

Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. Risk X: Avoid combination

Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider therapy modification

Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). Risk X: Avoid combination

Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. Risk X: Avoid combination

Reproductive Considerations

Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraceptive measures before beginning treatment, during therapy, and for 6 months after the last docetaxel dose. Patients with partners who could become pregnant should use effective contraceptives during therapy and for 3 months after the last docetaxel dose.

Pregnancy Considerations

An ex vivo human placenta perfusion model illustrated that docetaxel crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower docetaxel placental transfer (Berveiller 2012).

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to docetaxel may cause fetal harm. Formulations may contain alcohol, which is also associated with adverse fetal effects.

Some pharmacokinetic properties of docetaxel may be altered in pregnant women (van Hasselt 2014). Data related to the use of docetaxel for the treatment of breast cancer in pregnancy is limited. Use should be restricted for clinically urgent situations; use of other agents is preferred. The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).

A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).

Breastfeeding Considerations

It is not known if docetaxel is present in breast milk.

Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last docetaxel dose.

Monitoring Parameters

CBC with differential (prior to each cycle; monitor frequently in patients with hematologic toxicity), LFTs (bilirubin, ALT, AST, alkaline phosphatase; prior to each cycle; more frequently if clinically indicated), renal function. Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor for hypersensitivity reactions (particularly with the first and second infusion; patients with a history of paclitaxel hypersensitivity require close monitoring during initiation). Monitor for signs/symptoms of neurosensory symptoms, GI toxicity (eg, diarrhea, stomatitis, enterocolitis, neutropenic colitis), cutaneous reactions or severe skin toxicity, visual impairment, fluid retention (patients with existing effusions should be monitored closely during the first infusion for potential exacerbation), epiphora, canalicular stenosis, tumor lysis syndrome (prior to initiation and periodically during therapy), and second primary malignancies. A prompt comprehensive ophthalmic exam is recommended if vision impairment occurs.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.

Mechanism of Action

Docetaxel promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerization of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.

Pharmacokinetics

Exhibits linear pharmacokinetics at the recommended dosage range

Distribution: Extensive extravascular distribution and/or tissue binding; Vdss: 113 L (mean steady state)

Protein binding: ~94% to 97%, primarily to alpha1-acid glycoprotein, albumin, and lipoproteins

Metabolism: Hepatic; oxidation via CYP3A4 to metabolites

Half-life elimination: Terminal: ~11 hours

Excretion: Feces (~75%, <8% as unchanged drug); urine (~6%)

Pharmacokinetics: Additional Considerations

Hepatic function impairment: Total body clearance is reduced by average of 27% and AUC increased 38% in patients with mild to moderate hepatic function impairment (ALT and/or AST more than 1.5 × ULN concomitant with alkaline phosphatase more than 2.5 × ULN).

Pricing: US

Concentrate (DOCEtaxel Intravenous)

20 mg/mL (per mL): $26.40 - $365.15

80 mg/4 mL (per mL): $23.40 - $365.15

160 mg/8 mL (per mL): $22.95 - $365.15

Solution (DOCEtaxel Intravenous)

20 mg/2 mL (per mL): $26.40 - $194.31

80 mg/8 mL (per mL): $24.00 - $189.77

160 mg/16 mL (per mL): $20.48 - $189.77

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Adenex SV (LB);
  • Ai Su (CN);
  • Asdocel (AR);
  • Asodoc (CR, DO, GT, HN, MX, NI, PA, SV);
  • Axtere (ZA);
  • Belotaxel (KR);
  • Brexel (ID);
  • Camitotic (HU, LV, PL);
  • Daxotel (EG, SG, TH, VE, ZW);
  • Decexan (LK);
  • Dexotel (IN);
  • Docetax (BD, IN, PH, VE);
  • Docetere (AU);
  • Docetex (ZW);
  • Docexan (BD);
  • Doctere (ZA);
  • Dolectran (EC);
  • Doletran (PY);
  • Donataxel (EC);
  • Dotaxel (KR);
  • Doxecal (PH);
  • Doxel (TR);
  • Doxestad (PH);
  • Doxetal (JO);
  • Doxetasan (ID, LK, PH);
  • Eriox (AR);
  • Eutaxer (EG);
  • Hentaxel (PH);
  • Isotera (TW);
  • Monotaxel (KR);
  • Newtaxel-A (PH);
  • Newtaxell (VN);
  • Novotax (RU);
  • Novotaxel (LK);
  • Oncodocel (BR, CO, RU);
  • Oncotaxel (AU, SG, TH);
  • Pacancer (KR);
  • Taceedo (ET, PH, ZW);
  • Taxanit (CR, DO, GT, HN, MX, NI, PA, SV);
  • Taxanit RTU (CR, DO, GT, HN, NI, PA, SV);
  • Taxceus (DE, IT);
  • Taxelo (KR);
  • Taxomed (PE);
  • Taxotere (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BO, BR, CH, CI, CL, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, IE, IS, IT, JO, JP, KE, KR, LB, LI, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, TH, TN, TR, TW, TZ, UA, UG, UY, VE, VN, ZA, ZM, ZW);
  • Taxozen (KR);
  • Tedocad (BG);
  • Texot (AR, UY);
  • Tolnexa (HR, NL);
  • Tynen (HK);
  • Tyxan (TW);
  • Vexdo (PH);
  • Xi Cun (CN);
  • Zytax (LK)


For country code abbreviations (show table)
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.
  2. Ajani JA, Fodor MD, Tjulandin SA, et al, “Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma,” J Clin Oncol, 2005, 23(24):5660-7. [PubMed 16110025]
  3. Ajani JA, Moiseyenko VM, Tjulandin S, et al, “Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Cancer Adenocarcinoma: The V-325 Study Group,” J Clin Oncol, 2007, 25(22):3205-9. [PubMed 17664467]
  4. Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882-1887. doi:10.1093/annonc/mdn403 [PubMed 18669868]
  5. Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1 [PubMed 30982686]
  6. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  7. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621-3630. doi:10.1158/1078-0432.CCR-12-3791 [PubMed 23649003]
  8. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2013;189(3):834-839. doi:10.1016/j.juro.2012.10.068 [PubMed 23123371]
  9. Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009;27(3):331-335. doi:10.1007/s00345-009-0377-1 [PubMed 19214528]
  10. Basch E, Loblaw DA, Oliver TK, et al. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline [published online ahead of print September 8, 2014]. J Clin Oncol. [PubMed 25199761]
  11. Baselga J, Cortés J, Kim SB, et al, “Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer,” N Engl J Med, 2012, 366(2):109-19. [PubMed 22149875]
  12. Berveiller P, Vinot C, Mir O, et al, "Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model," Am J Obstet Gynecol, 2012, 207(6):514.e1-514.e7. [PubMed 23174392]
  13. Blohmer JU, Schmid P, Hilfrich J, et al, “Epirubicin and Cyclophosphamide Versus Epirubicin and Docetaxel as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomised Phase III Trial,” Ann Oncol, 2010, 21(7):1430-5. [PubMed 20089562]
  14. Burstein HJ, Manola J, Younger J, et al, “Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer,” J Clin Oncol, 2000, 18(6):1212-9. [PubMed 10715290]
  15. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  16. Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol. 2013;31(17):2123-2127. doi: 10.1200/JCO.2012.45.6574. [PubMed 23650421]
  17. Clarke SJ and Rivory LP, "Clinical Pharmacokinetics of Docetaxel," Clin Pharmacokinet, 1999, 36(2):99-114. [PubMed 10092957]
  18. Day FL, Leong T, Ngan S, et al, “Phase I Trial of Docetaxel, Cisplatin and Concurrent Radical Radiotherapy in Locally Advanced Oesophageal Cancer,” Br J Cancer, 2011, 104(2):265-71. [PubMed 21157450]
  19. Docetaxel injection [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; February 2021.
  20. Docetaxel injection [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2020.
  21. Docetaxel injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; November 2020.
  22. Docetaxel injection (non-alcohol formula) [prescribing information]. Burlington, MA: AMRI Burlington Inc; August 2021.
  23. Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. Pediatr Blood Cancer. 2013;60(7):1073-1082. [PubMed 23512831]
  24. Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57(2):191-198. [PubMed 21465637]
  25. Esteva FJ, Valero V, Booser D, et al, “Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer,” J Clin Oncol, 2002, 20(7):1800-8. [PubMed 11919237]
  26. Fizazi K, Foulon S, Carles J, et al; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1 [PubMed 35405085]
  27. Floyd J, Mirza I, Sachs B, et al, “Hepatotoxicity of Chemotherapy,” Semin Oncol, 2006, 33(1):50-67. [PubMed 16473644]
  28. Floyd JD, Nguyen DT, Lobins RL, et al, “Cardiotoxicity of Cancer Therapy,” J Clin Oncol, 2005, 23(30):7685-96. [PubMed 16234530]
  29. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21(1):25-30. doi:10.1089/thy.2010.0220 [PubMed 21162687]
  30. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-3024. doi:10.1200/JCO.2003.12.046 [PubMed 12837811]
  31. Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012;17(3):321. doi:10.1634/theoncologist.2010-0265 [PubMed 22363068]
  32. Garcia AA, Blessing JA, Vaccarell L, et al, “Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” Am J Clin Oncol, 2007, 30(4):428-31. [PubMed 17762444]
  33. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicenter, double-blind, randomized phase 3 trial. Lancet. 2014;384(9944):665-673. doi:10.1016/S0140-6736(14)60845-X [PubMed 24933332]
  34. George SL, Broster S, Chisholm JC, Brock P. Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma. J Pediatr Hematol Oncol. 2012;34(7):e295-297. [PubMed 22469940]
  35. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. [PubMed 22153890]
  36. Greco FA, Erland JB, Morrissey LH, et al, “Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin,” Ann Oncol, 2000, 11(2):211-5. [PubMed 10761758]
  37. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471 [PubMed 33939491]
  38. Harvey V, Mouridsen H, Semiglazov V, et al, “Phase III Trial Comparing Three Doses of Docetaxel For Second-Line Treatment of Advanced Breast Cancer,” J Clin Oncol, 2006, 24(31):4963-4970. [PubMed 17033039]
  39. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009;112(3):563-567. doi:10.1016/j.ygyno.2008.11.027 [PubMed 19135708]
  40. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824-2831. doi:10.1200/JCO.2002.11.050 [PubMed 12065559]
  41. Hensley ML, Miller A, O'Malley DM, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015;33(10):1180-1185. doi:10.1200/JCO.2014.58.3781 [PubMed 25713428]
  42. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242-249. doi:10.1200/JCO.2008.18.1545 [PubMed 19064973]
  43. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  44. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.
  45. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77. [PubMed 26719232]
  46. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598 [PubMed 20118214]
  47. Ji JH; Korean Cancer Study Group (KCSG), Yun T, Kim SB, et al, “A Prospective Multicentre Phase II Study of Cisplatin and Weekly Docetaxel as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (KCSG HN07-01),” Eur J Cancer, 2012, 48(17):3198-204. [PubMed 22795584]
  48. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177-1183. doi:10.1200/JCO.2008.18.4028 [PubMed 19204201]
  49. Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013;14(11):1121-1128. doi:10.1016/S1470-2045(13)70384-X [PubMed 24007746]
  50. Jones SE, Savin MA, Holmes FA, et al, "Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Operable Breast Cancer," J Clin Oncol, 2006, 24(34):5381-7. [PubMed 17135639]
  51. Kim S, François E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018;19(8):1094-1106. doi:10.1016/S1470-2045(18)30321-8 [PubMed 30042063]
  52. Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006 Jun;26(6):853-867. [PubMed 16716138]
  53. Kuo C, Kent PM, Logan AD, et al. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. Pediatr Blood Cancer. 2017;64(4):10.1002/pbc.26265. doi:10.1002/pbc.26265 [PubMed 28221727]
  54. Kushner DM, Connor JP, Sanchez F, et al, “Weekly Docetaxel and Carboplatin for Recurrent Ovarian and Peritoneal Cancer: A Phase II Study,” Gynecol Oncol, 2007, 105(2):358-64. [PubMed 17258800]
  55. Lansinger OM, Biedermann S, He Z, Colevas AD. Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. J Clin Oncol. 2021;39(32):3583-3590. doi:10.1200/JCO.21.01200 [PubMed 34357780]
  56. Leu KM, Ostruszka LJ, Shewach D, et al, “Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma,” J Clin Oncol, 2004, 22(9):1706-12. [PubMed 15117993]
  57. Li QQ, Liu MZ, Hu YH, et al, “Definitive Concomitant Chemoradiotherapy With Docetaxel and Cisplatin in Squamous Esophageal Carcinoma,” Dis Esophagus, 2010, 23(3):253-9. [PubMed 19732130]
  58. Li YF, Fu S, Hu W, et al, “Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,” Int J Gynecol Cancer, 2007, 7(4):739-63. [PubMed 17309673]
  59. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  60. Mackey JR, Martin M, Pienkowski T, et al, “Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide in Node-Positive Breast Cancer: 10-Year Follow Up of the Phase III Randomised BCIRG 001 Trial,” Lancet Oncol, 2013, 14(1):72-80. [PubMed 23246022]
  61. Maki RG, Wathen JK, Patel SR, et al, “Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002,” J Clin Oncol, 2007, 25(19):2755-63. [PubMed 17602081]
  62. Markman M, Kennedy A, Webster K, et al, “Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum,” J Clin Oncol, 2001, 19(7):1901-5. [PubMed 11283121]
  63. Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313. [PubMed 15930421]
  64. Marty M, Cognetti F, Maraninchi D, et al, "Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group," J Clin Oncol, 2005, 23(19):4265-74. [PubMed 15911866]
  65. Masood W, Shammas S, Saleem Z, et al. Comparative study of oral and IV dexamethasone premedication in the prevention of docetaxel induced allergic reactions. J Oncol Pharm Pract. 2022;28(1):96-100. doi:10.1177/1078155220984369 [PubMed 33626987]
  66. Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published correction appears in J Clin Oncol. 2016;34(11):1287]. J Clin Oncol. 2015;33(30):3488-3515 [PubMed 26324367]
  67. Mavroudis D, Papakotoulas P, Ardavanis A, et al, “Randomized Phase III Trial Comparing Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine as First-Line Treatment in Women With Advanced Breast Cancer,” Ann Oncol, 2010, 21(1):48-54. [PubMed 19906761]
  68. McCaffrey JA, Hilton S, Mazumdar M, et al, “Phase II Trial of Docetaxel in Patients With Advanced or Metastatic Transitional-Cell Carcinoma,” J Clin Oncol, 1997, 15(5):1853-7. [PubMed 9164195]
  69. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24(19):3075-3080. doi:10.1200/JCO.2005.03.1161 [PubMed 16809732]
  70. Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3(4):293-303. doi:10.3233/BLC-170126 [PubMed 29152553]
  71. Mora J, Cruz CO, Parareda A, et al, "Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel," J Pediatr Hematol Oncol, 2009, 31(10):723-9. [PubMed 19727011]
  72. Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” Lancet Oncol, 2011, 12(8):806-14. [PubMed 21276754]
  73. Mukai H, Katsumata N, Ando M, et al, “Safety and Efficacy of a Combination of Docetaxel and Cisplatin in Patients With Unknown Primary Cancer,” Am J Clin Oncol, 2010, 33(1):32-5. [PubMed 19786850]
  74. Muro K, Hamaguchi T, Ohtsu A, et al, “A Phase II Study of Single-Agent Docetaxel in Patients With Metastatic Esophageal Cancer,” Ann Oncol, 2004, 15(6):955-9. [PubMed 15151954]
  75. Navid F, Willert JR, McCarville MB, et al, “Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,” Cancer, 2008, 113(2):419-25. [PubMed 18484657]
  76. O'Shaughnessy J, Miles D, Vukelja S, et al, “Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results,” J Clin Oncol, 2002, 20(12):2812-23. [PubMed 12065558]
  77. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69. [PubMed 27400984]
  78. Palmerini E, Jones RL, Marchesi E, et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 2016;16:280. doi:10.1186/s12885-016-2312-3 [PubMed 27098543]
  79. Pasini F, de Manzoni G, Zanoni A, et al, “Neoadjuvant Therapy With Weekly Docetaxel and Cisplatin, 5-Fluorouracil Continuous Infusion, and Concurrent Radiotherapy in Patients With Locally Advanced Esophageal Cancer Produced a High Percentage of Long-Lasting Pathological Complete Response: A Phase 2 Study,” Cancer, 2013, 119(5):939-45. [PubMed 23165781]
  80. Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi160-vi170. doi: 10.1093/annonc/mdt199. [PubMed 23813932]
  81. Pectasides D, Glotsos J, Bountouroglou N, et al, “Weekly Chemotherapy With Docetaxel, Gemcitabine and Cisplatin in Advanced Transitional Cell Urothelial Cancer: A Phase II Trial,” Ann Oncol, 2002, 13(2):243-50. [PubMed 11886001]
  82. Perez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” Ann Oncol, 2012, 23(Suppl 7):167-73. [PubMed 22997449]
  83. Pointreau Y, Garaud P, Chapet S, et al, “Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Llarynx Preservation,” J Natl Cancer Inst, 2009, 101(7):498-506. [PubMed 19318632]
  84. Polovich M, Whitford JN and Olsen M, Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.
  85. Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-1715. doi:10.1056/NEJMoa070956 [PubMed 17960013]
  86. Pouessel D, Culine S, Becht C, et al, “Gemcitabine and Docetaxel as Front-Line Chemotherapy in Patients With Carcinoma of an Unknown Primary Site,” Cancer, 2004, 100(6):1257-61. [PubMed 15022294]
  87. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16(4):602-610. doi:10.1093/annonc/mdi126 [PubMed 15741225]
  88. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012;59(5):854-858. [PubMed 22302783]
  89. Rivera E, Mejia JA, Arun BK, et al, “Phase 3 Study Comparing the Use of Docetaxel on an Every-3-Week versus Weekly Schedule in the Treatment of Metastatic Breast Cancer,” Cancer, 2008, 112(7):1455-61. [PubMed 18300256]
  90. Roy A, Cunningham D, Hawkins R, et al, “Docetaxel Combined With Irinotecan or 5-Fluorouracil in Patients With Advanced Oesophago-Gastric Cancer: A Randomised Phase II Study,” Br J Cancer, 2012, 107(3):435-41. [PubMed 22767144]
  91. Ruhstaller T, Widmer L, Schuller JC, et al, “Multicenter Phase II Trial of Preoperative Induction Chemotherapy Followed by Chemoradiation With Docetaxel and Cisplatin for Locally Advanced Esophageal Carcinoma (SAKK 75/02),” Ann Oncol, 2009, 20(9):1522-8. [PubMed 19465425]
  92. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284. doi:10.1093/annonc/mdt182 [PubMed 23704196]
  93. Schrijvers D, Van Herpen C, Kerger J, et al, “Docetaxel, Cisplatin and 5-Fluorouracil in Patients With Locally Advanced Unresectable Head and Neck Cancer: A Phase I-II Feasibility Study,” Ann Oncol, 2004, 15(4):638-45. [PubMed 15033673]
  94. Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397-1410. doi:10.1016/S1470-2045(17)30622-8 [PubMed 28882536]
  95. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33(33):3874-3879. doi:10.1200/JCO.2015.60.7465 [PubMed 26438119]
  96. Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38(23):2677-2694. doi:10.1200/JCO.20.00866 [PubMed 32568633]
  97. Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res. 2017;23(3):649-657. doi:10.1158/1078-0432.CCR-16-0162 [PubMed 27301700]
  98. Sharma P, López-Tarruella S, García-Saenz JA, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24(23):5820-5829. doi:10.1158/1078-0432.CCR-18-0585 [PubMed 30061361]
  99. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  100. Shim HJ, Kim DE, Hwang JE, et al, “A Phase II Study of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin in Advanced Oesophageal Cancer,” Cancer Chemother Pharmacol, 2012, 70(5):683-90. [PubMed 22932694]
  101. Slamon D, Eiermann W, Robert N, et al, “Adjuvant Trastuzumab in HER2-Positive Breast Cancer,” N Engl J Med, 2011, 365(14):1273-83. [PubMed 21991949]
  102. Smallridge RC, Ain KB, Asa SL, et al; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104-1139. doi:10.1089/thy.2012.0302 [PubMed 23130564]
  103. Smith MR, Hussain M, Saad F, et al; ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115 [PubMed 35179323]
  104. Smyth JF, Smith IE, Sessa C, et al, “Activity of Docetaxel (Taxotere) in Small Cell Lung Cancer. The Early Clinical Trials Group of the EORTC,” Eur J Cancer, 1994, 30A(8):1058-60. [PubMed 7654428]
  105. Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203(5):902-909. doi:10.1097/JU.0000000000000688 [PubMed 31821066]
  106. Steinberg RL, Thomas LJ, O'Donnell MA, Nepple KG. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2015;1(1):65-72. doi:10.3233/BLC-150008 [PubMed 30561441]
  107. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509-1520. doi:10.1016/S1470-2045(16)30410-7 [PubMed 27686945]
  108. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-471. [PubMed 23602601]
  109. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-46. [PubMed 26244877]
  110. Symonds RP, Davidson SE, Chan S, et al. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecol Oncol. 2011;123(1):105-109. doi: 10.1016/j.ygyno.2011.06.001. [PubMed 21723596]
  111. Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512. doi:10.1056/NEJMoa040720 [PubMed 15470213]
  112. Taxotere (docetaxel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; May 2020.
  113. Taxotere (docetaxel) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; June 2020.
  114. Thiesen J and Kramer I, “Physico-Chemical Stability of Docetaxel Premix Solution and Docetaxel Infusion Solutions in PVC Bags and Polyolefine Containers,” Pharm World Sci, 1999, 21(3):137-41. [PubMed 10427584]
  115. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.
  116. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al, “Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,” J Clin Oncol, 2006, 24(31):4991-7. [PubMed 17075117]
  117. van Hasselt JG, van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014;25(10):2059-2065. [PubMed 24713311]
  118. Vasey PA, Jayson GC, Gordon A, et al, “Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma,” J Natl Cancer Inst, 2004, 96(22):1682-91. [PubMed 15547181]
  119. Vermorken JB, Remenar E, van Herpen C, et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704. doi:10.1056/NEJMoa071028 [PubMed 17960012]
  120. Zwerdling T, Krailo M, Monteleone P, et al; Children's Oncology Group. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer. 2006;106(8):1821-1828. [PubMed 16532433]
Topic 9381 Version 514.0